In this first randomised study of cfDNA testing vs. first trimester combined screening we demonstrate that even after exclusion of cases with increased NT or fetal anomalies and using the same risk cut-off of 1:100, the combination of first trimester ultrasound and cfDNA testing results in significantly lower false positive cases than first trimester combined screening.
Results: A total of 1907 PNDx tests were performed for a screening test indication during the study period. CFTS was the most common screening test indication with no significant variation by IRSAD quintiles or residential location (70.1%). The most socioeconomically advantaged women (IRSAD quintile 5) were significantly more likely to have NIPT as their indication for PNDx (26%) than the rest of the study population (14%, OR = 2.2, 95% CI 1.7-2.7). The percentage of PNDx that confirmed a major chromosome abnormality increased significantly with socioeconomic advantage, with the lowest diagnostic yield in IRSAD 1 (13%) and the highest in IRSAD 5 (23%) (p < 0.0001).
Conclusions:
There is significant variation in NIPT-indicated diagnostic testing according to socioeconomic status and geographical residence in our population. NIPT as a testing indication was overrepresented in the higher IRSAD quintiles and metropolitan residents. This trend was associated with socioeconomically disadvantaged women undergoing more invasive prenatal tests for false positive screening results than advantaged women.
